In the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently amended) A humanized monoclonal antibody that binds to Shiga toxin protein, comprising a constant region and a ~~murine~~ variable region, wherein said constant region contains at least part of a human immunoglobulin constant region and said ~~murine~~ variable region contains at least part of ~~a murine~~ an immunoglobulin variable region as shown in Figure 3 (SEQ ID NO: 21) or Figure 6 (SEQ ID NO: 42), wherein the antibody specifically reacts with Stxl or Stx2 antigen.

2. (Currently amended) The humanized monoclonal antibody of claim 1, having the same binding specificity as the antibody selected from the group consisting of murine 13C4 (ATCC Accession No. CRL 1794), murine 11E10 (ATCC Accession ~~NO.~~ No. CRL 1987), humanized 13C4 (H13C4), and humanized 11E10 (H11E10).

3-13. (Cancelled)

14. (Currently amended) The humanized monoclonal antibody of ~~claim 13~~ claim 1, wherein said ~~non-human~~ immunoglobulin variable region is from a mouse.

15-16. (Cancelled)

17. (Currently amended) The humanized monoclonal antibody of ~~claim 13~~ claim 1, wherein said human immunoglobulin constant region is selected from the group consisting of IgG, IgA, and IgM.

18. (Currently amended) The humanized monoclonal antibody of claim 17, wherein said human immunoglobulin constant region is IgG.

19. (Previously presented) A humanized monoclonal antibody which binds Shiga toxin type 2 and Shiga toxin type 2 variants, comprising a constant region and a variable region, wherein:

said constant region is IgG1-kappa, and

said variable region contains at least a part of the sequence as set forth in SEQ ID NO: 42 and SEQ ID NO: 44.

20. (Currently amended) A humanized monoclonal antibody which binds Shiga toxin type 2 and Shiga toxin type 2 variants, comprising a constant region and a variable region, wherein:

said constant region is IgGI-kappa, and

said variable region contains at least part of ~~the CDR sequences located as follows:~~

~~Heavy chain CDRs: CDR1-aa31-35~~

~~(SEQ ID NO:44) CDR2-aa50-66~~

~~CDR3-aa99-108~~

~~Light Chain CDRs: CDR1-aa24-40~~

~~(SEQ ID NO:42) CDR2-aa56-62~~

~~CDR3aa95-103.~~

CDR1 amino acids 31-35 of SEQ ID NO:44, CDR2 amino acids 50-66 of SEQ ID NO:44, CDR3 amino acids 99-108 of SEQ ID NO:44, CDR1 amino acids 24-40 of SEQ ID NO:42, CDR2 amino acids 56-62 of SEQ ID NO:42, or CDR3 amino acids 95-103 of SEQ ID NO:42.

21-22. (Cancelled)

23. (Previously presented) A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier or diluent.

24-28. (Cancelled)

29. (Currently amended) A pharmaceutical composition comprising the antibody of claim ~~13~~ 19 and a pharmaceutically acceptable carrier or diluent.

30-31. (Cancelled)

32. (Previously presented) A humanized monoclonal antibody that binds to a Shiga toxin protein comprising a human immunoglobulin constant region and a variable region,

wherein the variable region comprises amino acid sequences selected from the group consisting of amino acids 31-35 of SEQ ID NO: 44, amino acids 50-66 of SEQ ID NO: 44, amino acids 99-108 of SEQ ID NO: 44, amino acids 24-40 of SEQ ID NO: 42, amino acids 56-62 of SEQ ID NO: 42, and amino acids 95-103 of SEQ ID NO:42.

33. (Previously presented) A fragment of the antibody of claim 32 wherein the fragment binds a Shiga toxin protein.

34. (Previously presented) The humanized monoclonal antibody of claim 32 wherein the human constant region is selected from the group consisting of IgG, IgA and IgM.

35. (Previously presented) The humanized monoclonal antibody of claim 32 wherein the human constant region is IgG.

36. (Previously presented) The humanized monoclonal antibody of claim 32 wherein the human constant region is IgGl-kappa.

37. (Previously presented) The humanized monoclonal antibody of claim 32 wherein the variable region comprises the amino acid sequence of SEQ ID NO: 44.

38. (Currently amended) The humanized monoclonal antibody of claim 32 wherein the variable region comprises ~~he~~ the amino acid sequence of SEQ ID NO: 42.

39. (Previously presented) A pharmaceutical composition comprising an antibody of claim 32 and a pharmaceutically acceptable carrier or diluent.

40. (Previously presented) A pharmaceutical composition comprising an

antibody fragment of claim 32 and a pharmaceutically acceptable carrier or diluent.

41. (Previously presented) A monoclonal antibody selected from the group consisting of murine 13C4 (ATCC Accession No. CRL 1794), murine 11E10 (ATCC Accession No. CRL 1987), humanized 13C4 (H13C4) and humanized 11E10.

42. (Previously presented) The humanized monoclonal antibody of claim 20, wherein the variable region comprises amino acid sequences selected from the group consisting of amino acids 31-35 of SEQ ID NO: 44, amino acids 50-66 of SEQ ID NO: 44, amino acids 99-108 of SEQ ID NO: 44, amino acids 24-40 of SEQ ID NO: 42, amino acids 56-62 of SEQ ID NO: 42, and amino acids 95-103 of SEQ ID NO:42.

43. (Previously presented) The humanized monoclonal antibody of claim 1, wherein the human immunoglobulin constant region is as shown in Figure 3 (SEQ ID NO: 19) or Figure 6 (SEQ ID NO: 44).

44. (New) The pharmaceutical composition of claim 23, said composition comprising a first and second antibody of claim 1, wherein the first antibody of claim 1 specifically reacts with Stx2 antigen and the second antibody of claim 1 specifically reacts with Stx1 antigen.

45. (New) The pharmaceutical composition of claim 44, wherein the first antibody of claim 1 that specifically reacts with Stx2 antigen has the same binding specificity as h11E10 and the second antibody of claim 1 that specifically reacts with Stx1 antigen has the same binding specificity as h13C4.

46. (New) The pharmaceutical composition of claim 45, wherein the first antibody of claim 1 specifically reacts with Stx2 antigen contains at least part of an immunoglobulin variable region as shown in Figure 6 (SEQ ID NO: 42) and the second antibody of claim 1 that specifically reacts with Stx1 antigen contains at least part of an immunoglobulin variable region as shown in Figure 3 (SEQ ID NO: 21).

47. (New) The pharmaceutical composition of claim 29, further comprising a humanized monoclonal antibody that binds Stx1 antigen.

48. (New) The pharmaceutical composition of claim 47, wherein said humanized monoclonal antibody that binds Stx1 antigen has the same binding specificity as h13C4 and said antibody which binds Shiga toxin type 2 and Shiga toxin type 2 variants has the same binding specificity as h11E10.

49. (New) The pharmaceutical composition of claim 48, wherein said humanized antibody that binds Stx1 antigen comprises at least part of: CDR1 amino acids 31-35 of SEQ ID NO: 19, CDR2 amino acids 50-66 of SEQ ID NO: 19, CDR3 amino acids 99-111 of SEQ ID NO: 19, CDR1 amino acids 24-34 of SEQ ID NO: 21, CDR2 amino acids 50-56 of SEQ ID NO: 21, or CDR3 amino acids 89-97 of SEQ ID NO: 21.

50. (New) The pharmaceutical composition of claim 49, wherein said humanized antibody that binds Stx1 antigen comprises at least part of SEQ ID NO: 19 or SEQ ID NO: 21.

51. (New) The pharmaceutical composition of claim 39, further comprising a humanized monoclonal antibody that binds Stx1 antigen.

52. (New) The pharmaceutical composition of claim 51, wherein said humanized monoclonal antibody that binds Stx1 antigen has the same binding specificity as h13C4 and said antibody of claim 32 has the same binding specificity as h11E10.

53. (New) The pharmaceutical composition of claim 52, wherein said humanized antibody that binds Stx1 antigen comprises at least part of: CDR1 amino acids 31-35 of SEQ ID NO: 19, CDR2 amino acids 50-66 of SEQ ID NO: 19, CDR3 amino acids 99-111 of SEQ ID NO: 19, CDR1 amino acids 24-34 of SEQ ID NO: 21, CDR2 amino acids 50-56 of SEQ ID NO: 21, or CDR3 amino acids 89-97 of SEQ ID NO: 21.

54. (New) The pharmaceutical composition of claim 53, wherein said antibody of claim 32 comprises an IgG1 kappa human immunoglobulin constant region.

55. (New) The pharmaceutical composition of claim 53, wherein said humanized antibody that binds to Stx1 antigen comprises at least part of SEQ ID NO: 19 or SEQ ID NO: 21.